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Summary. In the platelet, it is well established that many
G-protein- and tyrosine kinase-coupled receptors stimulate
phospholipase-C-dependent Ca
2+ mobilization; however, the
extenttowhichsecondaryactivationofadenosine5¢-triphosphate
(ATP)-gated P2X1 receptors contributes to intracellular Ca
2+
responsesremainsunclear.Wenowshowthatselectiveinhibition
of P2X1 receptors substantially reduces the [Ca
2+]i increase
evoked by several important agonists in human platelets; for
collagen, thromboxane A2, thrombin, and adenosine 5¢-diphos-
hate (ADP) the maximal eﬀect was a reduction to 18%, 34%,
52%,and69%ofcontrol,respectively.Thedirectcontributionof
P2X1tothesecondaryCa
2+responsewasfargreaterthanthatof
either P2Y receptors activated by co-released ADP, or via
synergistic P2X1:P2Y interactions. The relative contribution of
P2X1 to the peak Ca
2+ increase varied with the strength of the
initial stimulus, being greater at low compared to high levels of
stimulation for both glycoprotein VI and PAR-1, whereas P2X1
c o n t r i b u t e de q u a l l ya tb o t hl o wa n dh i g hl e v e l so fs t i m u l a t i o no f
thromboxane A2 receptors. In contrast, only strong stimulation
of P2Y receptors resulted in signiﬁcant P2X1receptor activation.
ATP release was detected by soluble luciferin:luciferase in
response to all agonists that stimulated secondary P2X1receptor
activation. However, P2X1 receptors were stimulated earlier and
to a greater extent than predicted from the average ATP release,
which can be accounted for by a predominantly autocrine
mechanism of activation. Given the central role of [Ca
2+]i
increases in platelet activation, these studies indicate that ATP
should be considered alongside ADP and thromboxane A2 as a
signiﬁcant secondary platelet agonist.
Keywords:A T P ,C a
2+, collagen, P2X1, thrombin,
thromboxane A2.
Introduction
Platelets express three receptors gated by extracellular nucleo-
tides: P2X1,P 2 Y 1,a n dP 2 Y 12 [1,2]. P2X receptors are Ca
2+-
permeable ligand-gated non-selective cation channels, whereas
P2Y receptors are seven transmembrane domain receptors that
couple to cellular responses via the activation of heterotrimeric
G-proteins [3]. Although adenosine 5¢-diphoshate (ADP) was
initially believed to act at all three human platelet P2 receptors,
it is now clear that ADP and adenosine 5¢-triphosphate (ATP)
areselectivephysiologicalagonistsattheplateletP2YandP2X1
receptors, respectively [4]. The important role that P2Y1 and
P2Y12 receptors play during hemostasis and thrombosis is well
established [5,6]. In contrast, the relevance of P2X1 receptors to
platelet function has been questioned because they rapidly
desensitize [4] and their selective activation in vitro evokes a
transient shape change without signiﬁcant aggregation [7].
However, murine models demonstrate an important contribu-
tion of this ATP-gated non-selective cation channel to throm-
bosis,particularlyinsmallarteries[8,9].Oneexplanationforthe
major contribution of P2X1 to platelet activation in vivo is that
ATP released from dense granules contributes to signaling
events following initial stimulation by other agonists. In
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for P2X1 in the aggregation responses to low doses of collagen
and thrombin [8,10,11]. Whilst much work has been conducted
to characterize P2X1 involvement in downstream platelet
function, the extent to which P2X1 acts independently or in
synergy with other secondary mediators during the early stages
of platelet activation remains unclear. In the present study, we
have used measurements of the key platelet second messenger,
intracellular Ca
2+ ([Ca
2+]i), to examine the relative importance
ofP2X1receptorsaloneandincombinationwithP2Yreceptors
in the initial responses to a number of major agonists.
Methods
Preparation of platelet suspensions
Fura-2-loaded washed suspensions of human platelets from
informed, consenting donors were prepared using acid citrate
dextrose anticoagulant and treated with aspirin (100 lM)a n d
type VII apyrase (0.32 U mL
)1) as described elsewhere [7].
The study was approved by the University of Cambridge
Human Biology Research Ethics Committee. Platelets were
resuspended in nominally Ca
2+-free saline (in mM: 145 NaCl,
5 KCl, 1 MgCl2,1 0H E P E S ,1 0g l u c o s e ,t i t r a t e dt op H7 . 3 5
with NaOH) with type VII apyrase (0.32 U mL
)1). 2 mM
CaCl2 or 2 mM MgCl2 was added to the cuvette 30 s prior to
the agonist for studies in the presence and absence of external
Ca
2+, respectively.
[Ca
2+]i measurements
Fura-2 ratiometric ﬂuorescence measurements were conducted
at 37  C in a Cairn spectroﬂuorimeter system (Cairn Research
Limited, Faversham, Kent, UK) and converted to [Ca
2+]i as
described elsewhere using a dissociation constant for Ca
2+ of
224 nM [7].
Reagents
Collagen type I, as a suspension of native ﬁbers from bovine
tendon, was the gift of Ethicon Corporation (Somerville, NJ,
USA). Collagen-related peptide (CRP) with the sequence H–
GPC–(GPO)10–GPCG–NH2 was prepared and cross-linked
as described by Morton et al. [12]. ADP was treated with
hexokinase as described previously [13] and ATP levels
assessed by bioluminescent measurements (ATP Assay Kit,
Calbiochem-Novabiochem UK Ltd, Nottingham, UK, or
Chromo-lume Kit, Labmedics, Manchester, UK) using a
Model 400 lumi-aggregometer (Chrono-log Corporation,
Havertown, PA, USA). U46619 and thapsigargin were from
Calbiochem-Novabiochem UK Ltd. Cangrelor (AR-
C69931MX) was a kind donation from AstraZeneca (Moin-
dal, Sweden). All other reagents, including thrombin receptor
activating peptide (TRAP) speciﬁc for PAR1, ADP, a,b-
meATP, NF449 and MRS2179 were from Sigma-Aldrich
(Poole, UK).
Luminescence measurement of ATP secretion
ATP secretion from washed platelet suspensions was meas-
ured in a Model 400 lumi-aggregometer as above, following
the kit manufacturers guidelines. The luminescence channel
output was ampliﬁed tenfold before acquisition to computer.
Platelets used in luminescence studies were loaded with fura-
2 to provide parallel measurements of ATP secretion and
[Ca
2+]i under closely matched conditions. 600 nM a,b-
meATP did not interfere with the luciferin-luciferase assay
for ATP (Chen, Fung, and Mahaut-Smith, unpublished
observations).
Analysis
Sample records of [Ca
2+]i are representative of experiments
from ‡ four separate donors. The magnitude of Ca
2+
responses was assessed from the peak increase above prestim-
ulus level. Average values represent the mean ± SEM, with
statistical analysis performed using Studentsp a i r e dt-test.
Signiﬁcance is indicated at levels of 0.05 (*), 0.01 (**), 0.005
(***), and 0.001 (****).
Results
Conditions for maximal, selective inhibition of individual
platelet P2 receptor subtypes
To assess the relative contribution of the three platelet P2
receptors to [Ca
2+]i responses, we ﬁrst derived conditions that
provide maximal block, but with strict limits on selectivity.
Thus, whilst 3 lM was the minimum concentration of the
suramin derivative NF449 [14] required to completely block
P2X1 receptor-evoked Ca
2+ inﬂux, it also signiﬁcantly reduced
the ADP (1 lM)-evoked Ca
2+ release via P2Y receptors to
8 3±4 %o fc o n t r o l( F i g .1 ) .H o w e v e r ,1lM NF449 had no
signiﬁcant effect on ADP-evoked Ca
2+ release, yet still reduced
the peak response via P2X1 receptors to 11 ± 2% of control
(Fig. 1B,D). In comparison, P2Y responses to 10 lM ADP
were reduced to negligible levels (0.3 ± 0.2%) by 30 lM
MRS2179 (Fig. 1C,D), a concentration which has no effect
at P2Y12 receptors [15] or P2X1 responses (Fig. 1B). Higher
concentrations of MRS2179 were not employed as they started
to inhibit P2X1 receptors (Fung, unpublished observations).
However, 30 lM MRS2179 can be considered as an effective
blocker of most, if not all secondary Ca
2+ responses via P2Y
receptors as maximal local extracellular concentrations of ADP
are likely to be in the range 10–20 lM. This estimation is based
upon the surface-attached luciferase measurements of ATP by
Beigi et al. [16], and the fact that ATP and ADP are stored at
equal concentrations in the dense granules of human platelets
[17]. Because 1 lM cangrelor also had no signiﬁcant effect on
P2X1 (Fig. 1B), but maximally inhibits P2Y12 receptor
responses [18] without affecting P2Y1 receptors [19], these
results establish that 1 lM NF449, 1 lM cangrelor and 30 lM
MRS2179 provide maximal, selective antagonism of P2X1,
P2X1 receptor-dependent platelet Ca
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to selectively inhibit P2X1 receptor Ca
2+ inﬂux is desensiti-
zation in Ca
2+-free medium with a,b-meATP [10,20], which at
600 nM completely abolished P2X1 receptor-evoked Ca
2+
increases without inﬂuencing ADP-evoked Ca
2+ responses
(Fig. 1B,D).
The major role of P2X1 receptors in collagen-evoked Ca
2+
increases does not require co-activation of P2Y receptors and
principally involves glycoprotein VI
Selective inhibition of P2X1 receptors with 1 lM NF449
caused a large reduction of the Ca
2+ responses stimulated by
a low dose of collagen (0.5 lgm L
)1;F i g .2 A ) .T h ep e a kw a s
reduced to 18 ± 2% (P < 0.05) of control, similar to the
effect of P2X1 desensitization with 600 nM a,b-meATP
(reduction to 25 ± 9% of control; Fig. 2E). Importantly,
this conﬁrms that a,b-meATP predesensitization has equiv-
alent effects to simple direct blockade with NF449, and
desensitization was used as a preferred tool as it permitted
greater selective reduction of P2X1 receptor signals. The
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Fig. 2. The major role of P2X1 in collagen-evoked Ca
2+ signaling via
glycoprotein (GP) VI does not rely upon co-activation of P2Y receptors.
Representative (A–D, F) and average (E, G) [Ca
2+]i responses to collagen
(0.5 lgm L
)1, A–E) or collagen-related peptide (CRP; 25 or 250 ng mL
)1;
F, G). Average responses are shown as the percentage of a paired control.
Responses were studied in the presence and absence of a,b-meATP
(600 nM, added 90 s prior to agonist), NF449 (1 lM), MRS 2179 (MRS,
30 lM) and cangrelor (CNG, 1 lM), or a combination of these blockers as
shown, all added 60 s before agonist. All experiments were conducted in
t h ep r e s e n c eo fe x t e r n a lC a
2+ (2 mM).
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Fig. 1. Conditions for maximal, selective inhibition of P2X1 receptors.
Eﬀect of diﬀerent P2 receptor antagonists or pre-addition of a,b-meATP
on [Ca
2]i responses via P2X1 receptors (A,B, 10 lM a,b-meATP in saline
with 2 mM Ca
2+) or P2Y receptors (C,D, hexokinase-treated ADP in
nominally Ca
2+-free saline; 10 lM ADP for MRS 2179, 1 lM ADP for
other compounds). (A), (C) Representative recordings. (B), (D) Average
peak responses, as percentage of paired controls. 600 nM a,b-meATP was
added 90 s prior to the test agonist. In all ﬁgures, the asterisks above each
bar indicate the P-value relative to the paired control; ns, not signiﬁcant;
a,b, a,b-meATP; MRS, MRS 2179; CNG, cangrelor.
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2+
responses was far greater than that of P2Y receptors, as the
response was reduced to only 78 ± 3%, 88 ± 10% and
80 ± 4%, respectively, for MRS2179, cangrelor and these
two inhibitors combined. Combined blockade of P2X1 and
either P2Y1 or both P2Y1 and P2Y12 receptors was not
signiﬁcantly different from block/desensitization of P2X1
alone (P > 0.05; Fig. 2E). Thus, we were unable to further
explore possible synergy between P2X1 and P2Y receptors, as
reported previously in the platelet [21]. However, this synergy
may account for the lack of effect of MRS2179 on top of
a,b-meATP despite a small but signiﬁcant effect of MRS
2179 on its own.
Selective stimulation of glycoprotein (GP) VI with
25 ng mL
)1 CRP [22] evoked a [Ca
2+]i response
comparable to 0.5 lgm L
)1 collagen, which was reduced
to 24 ± 5% of control by a,b-meATP pre-addition
(Fig. 2F), similar to the effect of P2X1 inhibition on low
collagen concentrations. As observed for collagen [20], the
percentage contribution of P2X1 to GPVI-dependent signals
was less at higher concentrations of CRP (for example
a,b-meATP reduced the response to 200 ng mL
)1 CRP to
only 68 ± 4% of control; Fig. 2G). Together these data
suggest that GPVI represents the receptor by which collagen
stimulates secondary activation of P2X1 receptors.
P2X1 receptor inhibition by NF449, or desensitization by
a,b-meATP, does not block other platelet Ca
2+ entry pathways
Platelet G-protein-coupled or tyrosine kinase-linked recep-
tors have been previously proposed to stimulate Ca
2+ inﬂux
via store-dependent and store-independent pathways [23,24].
We have recently shown that NF449 and a,b-meATP do
not affect platelet store-independent cation currents using
direct electrophysiological measurements in the megakaryo-
cyte [13]. To assess effects on store-dependent Ca
2+ inﬂux,
intracellular Ca
2+ stores were depleted for 5 min with 1 lM
thapsigargin in Ca
2+-free medium followed by addition of
external Ca
2+ (Fig. 3). Neither 600 nM a,b-meATP nor
1 lM NF449 had any signiﬁcant effect on store-dependent
Ca
2+ inﬂux as the time to reach [Ca
2+]i levels of 500 or
1000 nM following Ca
2+ re-addition were unaffected
(Fig. 3A–D). The lack of effect of NF449 or a,b-meATP
on the initial thapsigargin-evoked Ca
2+ inﬂux also conﬁrms
that these P2X1-inhibiting reagents do not substantially alter
the platelet membrane potential. However, the later phase of
the Ca
2+ increase in these re-addition experiments was
slightly attenuated or delayed by P2X1 receptor inhibition,
although this was only signiﬁcant for the peak response for
a,b-meATP pre-addition (decrease to 89 ± 2% of control;
P < 0.001) and the time to peak for 1 lM NF449 (increase
to 167 ± 18% of control; P < 0.05). A reasonable
explanation for these effects is that high levels of Ca
2+
lead to ATP secretion [25], which ampliﬁes/accelerates the
peak Ca
2+ response through P2X1 receptor activation in
parallel to store-mediated Ca
2+ entry.
Role of P2X1 receptors in thrombin-evoked Ca
2+-responses
We next assessed the importance of P2X1 receptors during
responses to thrombin, the most potent known Ca
2+-mobil-
izing platelet agonist. The concentration–response curve for
thrombin (0.001–4.0 U mL
)1) in our platelet preparation is
shown in Fig. 4A. Desensitization of P2X1 receptors reduced
the peak response to thrombin in a concentration-dependent
manner, which was maximal at low to mid-range thrombin
concentrations (0.01–0.03 U mL
)1; see concentration–re-
sponse relationship in Fig. 4B and sample records at
0.03 U mL
)1 in Fig. 4C). In the absence of external Ca
2+,
a,b-meATP had no effect on the peak [Ca
2+]i increase evoked
by 0.03 U mL
)1 thrombin (97 ± 2% of the control response;
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Fig. 3. a,b-meATP and NF449 do not block store-dependent Ca
2+
inﬂux. Store-dependent Ca
2+ inﬂux was measured by addition of 2 mM
Ca
2+ after depletion of intracellular Ca
2+ stores in nominally Ca
2+-free
saline with the endomembrane Ca
2+-ATPase inhibitor, thapsigargin
(1 lM). 5 min after thapsigargin treatment, 600 nM a,b-meATP, 1 lM
NF449 or a water-vehicle control were added, followed a further 90 s later
by 2 mM Ca
2+. Representative traces are shown for a,b-meATP (A) and
NF449 (B) with their paired control. The average rate of initial Ca
2+
increase, as a direct measurement of store-dependent Ca
2+ inﬂux, was
assessed as the time to 500 nM (C) or 1000 nM (D), while the overall
response to Ca
2+ re-addition was assessed from the peak increase (E) and
time to peak (F).
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stored Ca
2+ levels or thrombin receptors.
At a thrombin concentration close to the EC50
(0.03 U mL
)1), no signiﬁcant effect was observed for
MRS2179 or cangrelor on the peak thrombin-evoked Ca
2+
increase (96 ± 5% and 110 ± 10% of control, respectively;
P > 0.05; Fig. 4D–F). This compares with reductions in peak
Ca
2+ responses to 52 ± 1% and 58 ± 10% of control with
a,b-meATP and NF449, respectively. Furthermore, this con-
tribution of P2X1 was not dependent upon interactions with
P2Y receptors as a,b-meATP reduced thrombin-evoked Ca
2+
increases to the same extent in the presence or absence of both
MRS 2179 and cangrelor (P > 0.05; Fig. 4F). The receptor
through which thrombin achieved P2X1 stimulation was
mainly PAR-1 as the response to an EC50 concentration of
TRAP speciﬁc for PAR-1 (10 lM) was reduced to 50 ± 6% of
the control response by a,b-meATP (not shown), which is not
signiﬁcantly different to the effect of losing P2X1 receptor
function during stimulation with 0.03 U mL
)1 thrombin
(P >0 . 0 5 ) .
Role of P2X1 during activation by the secondary agonists
ADP and thromboxane A2
We also examined the role of P2X1 receptors in response to
direct stimulation by thromboxane A2 and ADP, two further
platelet agonists with important roles in hemostasis and
thrombosis. The stable thromboxane A2 analogue, U46619,
activated its full range of [Ca
2+]i increases over only a narrow
range of concentrations; consequently, small and large
responses could be achieved with 0.5 and 1.0 lM U46619,
respectively. Inhibition of P2X1 receptors caused a
marked decrease in the peak [Ca
2+]i increase at both these
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2+ responses, partic-
ularly at low–mid-range levels of PAR receptor stimulation. (A) Dose–
response curve for the peak thrombin-evoked Ca
2+ increase; the data were
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Fig. 5. P2X1 receptors contribute to thromboxane A2 receptor-evoked
Ca
2+ increases at both high and low levels of stimulation. Representative
(A,B) and average (C,D) [Ca
2+]i responses to the thromboxane A2
mimetic, U46619, at concentrations that evoke small (0.5 lM;A , C )a n d
large (1 lM;B , D )p e a k[ C a
2+]i responses. (A) and (B) show representative
paired traces with and without 600 nM a,b-meATP (90 s exposure) to
desensitize P2X1 receptors. (C) and (D) show average peak [Ca
2+]i
increases as a percentage of a paired control following treatment with
600 nM a,b-meATP, 1.0 lM NF449, 30 lM MRS2179 (MRS), 1.0 lM
cangrelor (CNG), individually or in combination. All experiments were
conducted in the presence of external Ca
2+ (2 mM).
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reduced to 42 ± 11% and 38 ± 4%, respectively, by 1 lM
NF449 and 34 ± 7% and 35 ± 3%, respectively, after a,b-
meATP (Fig. 5C,D). Block of P2Y receptors had only small
effects on [Ca
2+]i responses to U46619 and, as observed for
collagen and thrombin, block of both P2X1 and P2Y receptors
was not signiﬁcantly different (P > 0.05) to the effect of P2X1
desensitization alone.
T h er o l eo fP 2 X 1 receptors in ADP-evoked responses is
difﬁcult to study because of contamination of commercial
samples with ATP [26]; however, hexokinase treatment reduces
the level of ATP to negligible levels (Fig. 6A). Desensitization
of P2X1 receptors had no effect on the Ca
2+ response to low
concentrations of ATP-free ADP (1 lM, P > 0.05;
Fig. 6B,D). However, maximal stimulation of P2Y receptors
with 30 lM hexokinase-treated ADP generated a noticeable
secondary phase of [Ca
2+]i increase, which was abolished by
a,b-meATP pre-addition (Fig. 6C). The secondary Ca
2+ spike
was variable between donors, and overall the average peak
ADP-evoked Ca
2+ increase was reduced to 69 ± 7%
(P < 0.01). The secondary Ca
2+ spike was not a result of
direct activation of P2X1 receptors by contaminating ATP for
two reasons. First, we estimate that the concentration of ATP
in 30 lM hexokinase-treated ADP is less than 1 nM,al e v e lt h a t
is unable to activate P2X1 receptors. Secondly, any direct P2X1
receptor activation would be rapid; yet the amplitude and rate
of initial ADP-evoked Ca
2+ increase was not altered by a,b-
meATP pre-addition (Fig. 6C). Therefore, it is likely that
30 lM ADP stimulates P2X1 via release of ATP (see below).
Early dense granule secretion generates only nanomolar levels
of bulk phase ATP
To examine the relationship between ATP release and the time
course of secondary P2X1 receptor activation, total ATP levels
were measured using luciferin/luciferase added to washed
platelet suspensions. Early ATP release was detected in
response to 30 lM ADP but not in response to 1 lM ADP
(Fig. 7A), which together with the data in Fig. 6 is consistent
with a requirement for ATP release for P2X1 activation.
Furthermore, early ATP release was observed in response to
collagen, thrombin and U46619 at concentrations of these
agonists that induce substantial P2X1 receptor activation
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Fig. 6. P2X1receptors contribute to P2Y receptor-evoked Ca
2+ responses
only at high levels of stimulation. (A) ATP-dependent luminescence signal
(from a luciferin:luciferase assay, in arbitrary units) following addition of
5 lM ATP, 100 lM commercial ADP (comm. ADP) and 1 mM ADP after
treatment with hexokinase (hex-ADP). (B,C) Representative paired
[Ca
2+]i responses to 1 or 30 lM ADP (hexokinase-treated) in the presence
or absence of 600 nMa,b-meATP (90 s, to desensitize P2X1receptors). (D)
Eﬀect of P2X1desensitization on peak ADP-evoked [Ca
2+]iresponses as a
percentage of a paired control. All experiments were conducted in the
presence of external Ca
2+ (2 mM).
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Fig. 7. Comparison of average bulk phase ATP levels and intracellular
Ca
2+ responses following stimulation by multiple agonists; evidence for
autocrine activation of P2X1 receptors. (A) Eﬀect of collagen
(0.5 lgm L
)1), thrombin (0.03 U mL
)1), U46619 (1 lM)a n dA D P( 1a n d
30 lM) on extracellular ATP levels measured using the luciferin–luciferase
ﬁreﬂy assay. The peak luminescence signal for a range of known ATP
concentrations was used to calibrate the agonist-evoked signals. (B)
Superimposition of the P2X1-dependent Ca
2+ increase and ATP secretion
evoked by 0.5 lgm L
)1 collagen. The dashed line corresponds to the peak
contribution by P2X1, which occurs when the average extracellular ATP
level is predicted to stimulate 10% of maximal P2X1 receptor activation.
All experiments were conducted in the presence of external Ca
2+ (2 mM).
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was only 10–30 nM during the ﬁrst 30 s, when P2X1 receptors
played a major role in the [Ca
2+]i increases. To examine the
temporal relationship between secretion and Ca
2+-mobiliza-
tion, the P2X1-dependent Ca
2+ response to 0.5 lgm L
)1
collagen was derived from recordings in the presence and
absence of a,b-meATP and compared to the percentage P2X1
receptor activation. The latter was calculated from the ATP
concentration–response relationship of P2X1 receptors follow-
ing complete inhibition of G-protein-coupled receptor Ca
2+
responses with a prostacyclin concentration that has no effect
on P2X1 receptors (Fung and Mahaut-Smith, unpublished
observations; Fig. 7B). This temporal comparison shows that
the average extracellular ATP concentration increases with a
delayed time course relative to the P2X1-dependent Ca
2+
increase. This difference can be accounted for by a predom-
inantly autocrine mechanism of P2X1 receptor activation as
ATP increases near thesites of granule release will belarger and
more rapid than in the bulk phase.
Discussion
An increase in [Ca
2+]i is used by a wide range of platelet
agonists as a key signal to activate downstream events. On its
own, [Ca
2+]i increases within the physiological range can
activate most functional responses in the platelet including
shapechange, aggregation, secretionandprocoagulant activity,
although Ca
2+-mobilization normally operates in tandem with
other signaling pathways such as tyrosine kinases, PI 3-kinase
and inhibition of cAMP production [25,27]. The central role of
Ca
2+ in hemostasis and thrombosis is demonstrated by the
ability of cytosolic BAPTA (a Ca
2+ chelator) to block or
markedly inhibit a number of mainstream platelet responses
such as inside-out activation of aIIbb3, procoagulant activity
and arachidonate production [28–30]. The present study shows,
for the ﬁrst time, that secondary activation of P2X1 receptors
represents a major means by which both G-protein-coupled
and tyrosine kinase-coupled receptors elevate [Ca
2+]i inde-
pendently of ADP-activated P2Y receptors. This enhancement
of the initial Ca
2+ responses may explain the previously
reported ability of P2X1 receptors to potentiate aggregation at
low levels of collagen and thrombin [8,10,11]. This general role
of P2X1 receptors as a secondary Ca
2+ inﬂux pathway could
also help explain the resistance to thrombosis displayed by
P2X1
)/) mice [8] and the enhanced thrombotic phenotype of
mice overexpressing human P2X1 receptors [9].
Platelet receptors coupled to phospholipase-C activation
mobilize Ca
2+ by a combination of IP3-dependent store
release and inﬂux across the plasma membrane [25]. The
current view is that these inﬂux pathways consist of ion
channels activated by either intracellular Ca
2+ store depletion
(store-operated Ca
2+ inﬂux) or the products of PLC such as
diacylglycerol (termed store-independent Ca
2+ inﬂux)
[13,23,24]. We now show that P2X1 receptors should be
considered as a signiﬁcant additional contributor to early
Ca
2+ inﬂux in the platelet following stimulation by agonists
acting via G-protein-coupled receptors and tyrosine-kinase-
coupled receptors.
We have previously shown that P2X1is able to potentiate the
non-selectivecationchannelcoupledtoP2Yreceptorsinmurine
megakaryocytes and to accelerate and amplify the P2Y-evoked
Ca
2+ mobilization in suspensions of human platelets [21].
Although such synergy may exist when both P2X1 and P2Y
receptorsareactive,thepresentstudyshowsthatP2X1doesnot
rely upon interactions with co-activated P2Y receptors to
contribute as a secondary Ca
2+-elevating pathway in the
platelet. Serotonin release from dense granules also has little or
noroleintheCa
2+responsesintheseexperimentsasamaximal
concentration of serotonin (1 lM) evoked a Ca
2+ increase of
<1 5n M, and 100 nM methiothepin (a concentration that
blocked responses to 1 lM serotonin) had no signiﬁcant effect
on the Ca
2+ increase evoked by 1 lMU46619 (109.5 ± 13.2%
of control; P > 0.05). A likely explanation for the important
independent role of P2X1 is that the primary agonist already
stimulates the phospholipase-C-dependent Ca
2+ ﬂuxes subse-
quently targeted by released ADP via P2Y receptors, whereas
P2X1 receptor-cation channels represent a separate route for
elevatingCa
2+
.Inaddition,weshowthatP2X1receptorscanbe
activated only when small total amounts of ATP are released,
thus allowing this pathway to contribute at low levels of dense
granule secretion. Moreover, our experiments were conducted
in the presence of apyrase, indicating the ability of ATP to
activate P2X1receptors even in the presence of signiﬁcant levels
of ectonucleotidase activity. The rapid kinetics of P2X1 activa-
tionbyitsligand[4]mostlikelyaccountforitsefﬁcientactivation
even in the presence of ectonucleotides. However, this role for
ATPshouldnotreducethewell-establishedimportanceofother
released compounds such as ADP and thromboxane A2.
In particular, because P2X1 causes elevation of only Ca
2+
(and Na
+), stimulation of complementary signaling pathways
by P2Y12 receptors remains crucial for collagen and thromb-
oxaneA2 receptor-evoked aggregation [1,2].
Two pieces of evidence suggest that secondary activation of
P2X1 receptors occurs via an autocrine rather than a paracrine
manner. First, the bulk phase ATP level when P2X1 maximally
contributes is sufﬁcient to activate less than 10% of P2X1
receptors (Fig. 7B). Secondly, P2X1 receptors contribute to the
collagen-evoked Ca
2+ increase earlier than the average extra-
cellular ATP increases (Fig. 7B). These observations can be
explained when it is considered that, following secretion, the
extracellular ATP concentration at the plasma membrane
surface will increase earlier, and be far greater in magnitude
compared to the average level measured by soluble lucifer-
in:luciferase. Localization of P2X1receptors at sites of secretion
may also explain how ATP release can so efﬁciently activate
P2X1 receptors. Although there is no direct evidence for such
localization at present, lipid rafts may play an important role as
these microdomains in platelets contain both P2X1 receptors
and SNARE proteins, and raft disruption leads to inhibition of
P2X1 responses and exocytosis [31,32].
In conclusion, we show that P2X1 receptors can represent a
signiﬁcant pathway for early Ca
2+-mobilization following
916 C. Y. E. Fung et al
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G-proteins and tyrosine kinases in the platelet. Thus, P2X1
receptors should be considered alongside store-operated and
store-independent channels as an important route for Ca
2+
inﬂux, and therefore to be a more signiﬁcant potential
antithrombotic target than previously recognized.
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